Actelion announces change in its management structure - Otto Schwarz appointed Chief Operating Officer
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion announces change in its management structure - Otto Schwarz appointed
Chief Operating Officer
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Actelion Ltd (SIX: ATLN) announced today that Otto Schwarz has been appointed
Chief Operating Officer (COO). Otto Schwarz joined Actelion in 2008 as Head of
Business Strategy & Operations. In addition to Commercial Operations and
Business Strategy he assumes responsibility for Corporate Services, Global
Quality Management and Corporate Communications, with all three departments
retaining their respective Heads.
Jean-Paul Clozel, M.D and Chief Executive Officer commented: "Otto Schwarz has
demonstrated his leadership and managerial skills by growing our product sales
in all markets worldwide as well as by expanding our global footprint. I am
convinced that Actelion will continue to greatly benefit from his new expanded
role with his drive for both operational and commercial excellence."
Jean-Paul Clozel concluded: "Otto's new role will allow me to focus even more on
strategic matters. Together, we are committed to move Actelion to the next stage
- advancing value creation for all stakeholders by turning innovation into
successful medicines that change patients' lives. Actelion will continue to
focus on orphan drugs and specialist markets and to collaborate, whenever
appropriate, with third parties for other indications. We will also continue to
evaluate in-licensing and acquisitions and act decisively when we identify
value-adding opportunities."
Actelion Executive Committee with five core members
Actelion has also adapted the membership of its Executive Committee (AEC),
chaired by Jean-Paul Clozel, to the needs of a growing organization and to
strengthen leadership and governance. The Executive Committee members comprise:
- Jean-Paul Clozel (Chief Executive Officer)
- Otto Schwarz (Chief Operating Officer, Executive VP)
- Andrew Oakley (Chief Financial Officer, Executive VP)
- Guy Braunstein (Head Global Clinical Development, Executive VP)
- Nicholas Franco (Chief Business Development Officer, Executive VP)
In addition to this core group, the extended AEC includes the following members:
- Christian Albrich (Head Global Human Resources, Senior VP)
- Marian Borovsky (Group General Counsel, Senior VP)
- Martine Clozel (Chief Scientific Officer, Senior VP)
- Roland Haefeli (Head Investor Relations and Public Affairs, Senior VP)
In line with the focus on strategic matters that includes driving innovation,
the Chief Executive Officer will maintain the three co-heads of Research as
direct reports: Beat Steiner (Drug Discovery, Biology), Thomas Weller (Drug
Discovery, Chemistry) and Martine Clozel (Drug Discovery, Pharmacology and
Preclinical Development).
The Group Compliance Officer, Peter Herrmann, will report to both the Chief
Executive Officer as well as to the Nominating and Governance Committee of the
Board of Directors, to ensure continued focus on corporate compliance.
Other changes
- Isaac Kobrin, previously Chief Medical Officer, will take up a new
role to plan and ultimately lead a biotech startup separate from Actelion that
will undertake the clinical development of its non-core compounds.
- - Simon Buckingham, previously Head Global Corporate and Business
Development, will take up a new role (on a part-time basis) leading special
projects and advising on corporate strategic matters.
All changes come into effect on Tuesday, 07 June 2011. More information about
Actelion's management structure and management members can be found on
www.actelion.com.
###
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1521550/457745.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1521550]
Unternehmensinformation / Kurzprofil:
Datum: 07.06.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 55338
Anzahl Zeichen: 6536
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion announces change in its management structure - Otto Schwarz appointed Chief Operating Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
